A key MRSA strain appears to predate, by more than 100 years, the advent of the antibiotic era.
A study conducted in 15 hospitals found that discontinuing contact precautions for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) did not result in increased healthcare-associated infection (HAI) rates, researchers reported today in Infection Control & Hospital Epidemiology.
New data from the European Centre for Diseases Prevention and Control (ECDC) show a dramatic drop in community antibiotic use across Europe during the first year of the COVID-19 pandemic.
Three more Ebola cases, one of them fatal, were reported in the Democratic Republic of the Congo's (DRC's) latest resurgence near Beni in North Kivu province, according to a World Health Organization (WHO) DRC office tweet today. The case total is now five including three deaths, said the World Health Organization (WHO) African regional office today on Twitter.
After years of decline, US hospitals saw significant increases in HAIs.
A quality improvement (QI) program combining clinician education, clear and concise recommendations, and decision support was associated with a safe reduction in vancomycin use in a pediatric intensive care unit (PICU), researchers reported today in Pediatrics.
Multidrug-resistant organisms (MDROs) were isolated in more than a quarter of South Korean patients with confirmed COVID-19 pneumonia and microbial culture results, with corticosteroid use identified as a significant risk factor, researchers reported yesterday in the American Journal of Infection Control.
Implementation of a test that provides rapid bacterial identification and susceptibility results from positive blood cultures shortened the time to optimal antibiotic therapy and reduced unnecessary antibiotic exposure in hospitalized patients with bacteremia, researchers reported late last week in the Journal of Antimicrobial Chemotherapy.
CARB-X announced today that it is awarding Phico Therapeutics of Cambridge, United Kingdom, up to $5.3 million to develop an intravenous bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Secondary analysis of patients from a postdischarge decolonization trial of methicillin-resistant Staphylococcus aureus (MRSA) carriers found that re-hospitalization for MRSA was associated with extensive exposure to non-MRSA antibiotics and Clostridioides difficile infection (CDI), researchers reported today in Infection Control & Hospital Epidemiology.
